Gainers

• Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market session. The market value of their outstanding shares is at $89.6 million.
• Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.08% to $7.21. The market value of their outstanding shares is at $3.6 million.
• Orthofix Medical (NASDAQ:OFIX) stock rose 9.65% to $10.9. The company's market cap stands at $377.9 million.
• Bioventus (NASDAQ:BVS) stock moved upwards by 6.01% to $11.11. The market value of their outstanding shares is at $666.2 million.
• Lixte Biotechnology Hldgs (NASDAQ:LIXT) shares moved upwards by 4.85% to $7.56. The company's market cap stands at $133.3 million.
• Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 4.68% to $0.3. The company's market cap stands at $4.6 million.

Losers

• Basel Medical Group (NASDAQ:BMGL) shares decreased by 12.3% to $7.32 during Thursday's after-market session. The market value of their outstanding shares is at $11.0 million.
• SL Science Holding (NASDAQ:SLBT) stock decreased by 11.36% to $5.31. The company's market cap stands at $2.4 billion.
• Veraxa Biotech Holding (NASDAQ:VRXA) shares fell 9.32% to $1.85. The company's market cap stands at $243.9 million.
• AdaptHealth (NASDAQ:AHCO) shares declined by 7.07% to $10.0. The market value of their outstanding shares is at $1.4 billion.
• CDT Equity (NASDAQ:CDT) shares decreased by 6.85% to $0.46. The company's market cap stands at $2.5 million.
• OPKO Health (NASDAQ:OPK) stock declined by 5.93% to $1.43. The company's market cap stands at $1.1 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.